Evidence map›Paper›PMID 37550212›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2023

[Analysis on the clinical efficacy and adverse reactions of blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia].

Y J Shi, Y Han, Y Wang, D F Mao, J L Zhang, R Xi, H Bai, T Wu

Open access · greenAbstract read
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Y J ShiDepartment of Hematology, the 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Amy, Lanzhou 730050, China.
Y HanDepartment of Hematology, the 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Amy, Lanzhou 730050, China.
Y WangDepartment of Hematology, the 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Amy, Lanzhou 730050, China.
D F MaoDepartment of Hematology, the 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Amy, Lanzhou 730050, China.
J L ZhangDepartment of Hematology, the 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Amy, Lanzhou 730050, China.
R XiDepartment of Hematology, the 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Amy, Lanzhou 730050, China.
H BaiDepartment of Hematology, the 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Amy, Lanzhou 730050, China.
T WuDepartment of Hematology, the 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Amy, Lanzhou 730050, China.
307th Hospital of Chinese People’s Liberation Army · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, BispecificAntineoplastic AgentsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansTreatment OutcomeAntibodies, BispecificAntineoplastic Agentsblinatumomab

Identifiers

PMID37550212
PMCPMC10450561
OpenAlexW4385680826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.